Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Autoimmune Disease Therapeutics Market $185 Billion by 2029

The global market for autoimmune disease therapeutics anticipated to attain $185 billion by 2029, growing moderately at a CAGR of 3.7% over the forecast period, driven by increasing prevalence of autoimmune diseases and immune-related secondary disorders, multiple new product launches, and rising cost for treatments.

Global Autoimmune Disease Therapeutics Market

Autoimmune diseases (ADs) are a family of more than 80 chronic, and often disabling, illnesses broadly characterized by immune system dysfunction leading to the loss of tolerance to self-antigens, presence of increased level of autoantibodies, inflammatory and mediatory cells and resulting chronic inflammation. Collectively, ADs are common, affecting between 5-9% of the population and are of considerable personal and public health burdens. The reasons for their high prevalence, gender and ethnic disparities and rising incidence and prevalence remain unclear.

  • Autoimmune diseases (AIDs) are often co-associated, and about 25% of patients with one AID tend to develop other comorbid AIDs. AIDs are classified into one of the following systems such as gastrointestinal, neuronal, eye, cutaneous, musculoskeletal, kidneys and lungs, cardiovascular, hematopoietic, endocrine, and multiple.
    • Some common diseases that are generally considered autoimmune include atopic dermatitis (AD), celiac disease, coeliac disease, inflammatory bowel disease (IBD), multiple sclerosis (MS), rheumatoid arthritis (RA), diabetes mellitus type 1, ulcerative colitis (UC), Chron’s disease (CD), Graves’ disease, psoriasis, and systemic lupus erythematosus (SLE).
  • About 24 million (~7.5%) people in the United States are affected by an autoimmune disease. Women are more commonly affected than men. ADs are common, with an estimated prevalence of 3,225/100,000.

Treatment depends on the type and severity of the condition. Nonsteroidal anti-inflammatory drugs (NSAIDs) and immunosuppressants are often used. Intravenous immunoglobulin may also occasionally be used. While treatment usually improves symptoms, they do not typically cure the disease.

  • Traditional treatment options include immunosuppressant drugs to reduce the immune response against the body’s own tissues, such as NSAIDs to reduce inflammation, glucocorticoids to reduce inflammation, disease-modifying anti-rheumatic drugs (DMARDs) to decrease the damaging tissue and organ effects of the inflammatory autoimmune response.
  • More advanced therapies aim to be less toxic to the patient and have more specific targets include monoclonal antibodies that can be used to block pro-inflammatory cytokines, antigen-specific immunotherapy which allows immune cells to specifically target the abnormal cells that cause autoimmune disease, co-stimulatory blockade that works to block the pathway that leads to the autoimmune response, and regulatory T cell therapy that utilizes this special type of T cell to suppress the autoimmune response.

The global market for autoimmune disease therapeutics research report provides market size ($million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031).

The global market for autoimmune disease therapeutics segmented by indication (ankylosing spondylitis, atopic dermatitis, Crohn’s disease, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, nasal polyps, ulcerative colitis, urticaria), application / system (dermatology, musculoskeletal disorders, gastroenterology, central nervous system, others), and geography.

  • Based on the applications or systems, the musculoskeletal system (ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis) segment accounted for the largest share of the total autoimmune disease treatment market, followed by the dermatology segment.
    • Among the dermatology, musculoskeletal, and gastroenterology systems, the psoriasis, rheumatoid arthritis, and Crohn’s disease indication sub-segments led the global AD treatment market, respectively.
    • The dermatology system segment consisting of autoimmune diseases (atopic dermatitis, psoriasis, urticaria) predicted to grow at the fastest rate during the forecast period, followed by the nasal polyps segment.
    • The gastroenterology system (Crohn’s disease, ulcerative colitis), and musculoskeletal system (ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis) segments estimated to grow moderately, while the central nervous system (multiple sclerosis) segment expected to continue a slight declining trend during the next few years.

The global market for autoimmune disease treatment research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of the geographical distribution, the North America region dominated the global AD therapeutics market, followed by the Europe region, and also expected to grow at the fastest CAGR over the next few years.
    • The autoimmune disease is recognized as a major health crisis in the United States. Today, 50 million Americans with 80% of women suffer one or more autoimmune conditions. That is, one in 12 Americans and one in 9 women have an autoimmune disease.
      • According to the National Institutes of Health (NIH), more than 24 million people have an autoimmune disease and the prevalence is increasing in the U.S.
    • In Europe, the prevalence of autoimmunity is also rising. In the UK alone, the incidence of various autoimmune diseases is increasing at ranges between 3% and 9% year on year.
      • The direct and indirect costs for just three autoimmune diseases alone (type 1 diabetes, rheumatoid arthritis, and multiple sclerosis) currently add up to more than £13 billion per year in the UK.
    • In addition, people from developing nations such as in Asia and Southeast Asia are also developing the same rates of autoimmune disease as the North America and Europe regions.

In addition, the global market for autoimmune disease therapeutics report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for autoimmune disease treatment and profiled in this report include AbbVie, Inc., AstraZeneca plc, Biogen, Inc., Bristol Myers Squibb Company, Eli Lilly & Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Roche Holding AG, Sanofi S.A., and Takeda Pharmaceutical Co., Ltd.

  • Indication
    • Ankylosing Spondylitis
    • Atopic Dermatitis
    • Crohn’s Disease
    • Multiple Sclerosis
    • Psoriasis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Nasal Polyps
    • Ulcerative Colitis
    • Urticaria
  • Application (System)
    • Dermatology (Atopic Dermatitis, Psoriasis, Urticaria)
    • Musculoskeletal Disorders (Ankylosing Spondylitis, Psoriatic arthritis, Rheumatoid Arthritis)
    • Gastroenterology (Crohn’s Disease, Ulcerative Colitis)
    • Central Nervous System (Multiple Sclerosis)
    • Others (Nasal Polyps)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • AbbVie, Inc.
    • AstraZeneca plc
    • Biogen, Inc.
    • Bristol Myers Squibb Company
    • Eli Lilly & Company
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Roche Holding AG
    • Sanofi S.A.
    • Takeda Pharmaceutical Co., Ltd.

To request Table of Contents and Sample Pages of this report:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com